Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The statement also said, in part, that "robust data" supporting Wegovy's "meaningful and unique benefits continue to grow" and that in addition to "offering significant and sustained weight loss ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

Novo Nordisk told Reuters in a statement that a similar dose of Wegovy led to greater weight loss in a 2021 trial and one earlier this year than what was observed in the recent study. The company ...